Health Canada Clarifies Position On Biosimilar Switching
As part of its update to a fact sheet on biologics and biosimilars, Health Canada has clarified its position on biosimilar switching.
You may also be interested in...
Alberta has become the latest Canadian province to expand its biosimilar switching program to cover adalimumab biosimilars to Humira.
New Brunswick has become the latest Canadian province to introduce a biosimilar switching program, with the newly-introduced scheme covering several biologic molecules.
British Columbia has expanded its biosimilar switching program to cover patients being treated with Humira in the Canadian province.